Peter MacCallum Cancer Centre

Treatment Characteristics and Real-World Progression-Free Survival in Patients With Unresectable Stage III NSCLC Who Received Durvalumab After Chemoradiotherapy: Findings From the PACIFIC-R Study (2022) Girard N, Bar J, Garrido P, Garassino MC, McDonald F, Mornex F, Filippi AR, et al. Journal article Grade 4 Neutropenia Secondary to Immune Checkpoint Inhibition — A Descriptive Observational Retrospective Multicenter Analysis (2021) Zaremba A, Kramer R, De Temple V, Bertram S, Salzmann M, Gesierich A, Reinhardt L, et al. Journal article Survey of Challenges in Access to Diagnostics and Treatment for Neuroendocrine Tumor (NET) Patients (SCAN): PRRT in the Treatment of Neuroendocrine Tumor (NET) Patients (2021) Dureja S, Kolarova T, Mcdonnell M, Van Genechten D, Bouvier C, Gellerman E, O'Toole D, et al. Conference contribution Pattern of invasion in stage I mucinous ovarian cancer is prognostic within 2-years of diagnosis (2021) Meagher N, Koebel M, Anderson L, Tan A, Bolithon A, Anglesio M, Cohen P, et al. Conference contribution Hematological immune related adverse events after treatment with immune checkpoint inhibitors (2021) Kramer R, Zaremba A, Moreira A, Ugurel S, Johnson DB, Hassel JC, Salzmann M, et al. Journal article Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group (2021) Moreau P, Kumar SK, San Miguel J, Davies F, Zamagni E, Bahlis N, Ludwig H, et al. Journal article, Review article Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial. (2021) Bottomley A, Coens C, Mierzynska J, Blank CU, Mandalà M, Long GV, Atkinson VG, et al. Journal article Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial. (2021) Eggermont AM, Blank CU, Mandalà M, Long GV, Atkinson VG, Dalle S, Haydon AM, et al. Journal article Matching-Adjusted Indirect Comparison of Ribociclib Plus Fulvestrant versus Palbociclib Plus Letrozole as First-Line Treatment of HR+/HER2-Advanced Breast Cancer (2021) Fasching P, Delea TE, Lu YS, De Boer R, Hurvitz SA, Moynahan A, Chandiwana D, et al. Journal article Refined cut-off for TP53 immunohistochemistry improves prediction of TP53 mutation status in ovarian mucinous tumors: implications for outcome analyses (2021) Kang EY, Cheasley D, LePage C, Wakefield MJ, da Cunha Torres M, Rowley S, Salazar C, et al. Journal article